SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a significant rebound following a period of intense short selling and recent earnings. Community members are actively discussing the potential for a short squeeze, citing high short interest and positive analyst ratings, and celebrating the stock's resilience amid market volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending as investors react to the company's announcement regarding the completion of its BlueBird 6 satellite and the planned launch schedule, generating excitement about upcoming milestones. The community is buzzing with bullish sentiment, anticipating new all-time highs and significant long-term growth potential. Some traders are closely monitoring short positions and expecting a potential squeeze.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to a broader crypto market rally and recent strategic restructuring, including the sale of its loyalty business and appointment of a fintech veteran to its board. The community is actively discussing the potential for a short squeeze and the company's transformation into a pure-play digital asset platform. Bullish sentiment is growing, with some eyeing prior highs and speculating about future partnerships and expansion.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending due to a mix of positive price action and news of increased competition in the stablecoin space. Community members are debating whether the stock will continue its upward momentum or face a pullback due to potential rate cuts impacting revenue. Traders are actively discussing technical levels and potential short squeezes, with some highlighting the impact of insider selling and upcoming share unlock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss potential catalysts, including upcoming data presentations at the World Muscle Society (WMS) Congress and the anticipation of positive news regarding SRP-9003. Community members are weighing the potential for a short squeeze given the stock's high short interest, with some expressing optimism for a significant price increase and buyout speculation, while remaining cautiously optimistic.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending due to significant call buying activity and a recent price surge, sparking bullish sentiment. The community is actively discussing potential price targets and the correlation with Bitcoin's movements, while also debating its valuation relative to peers like Robinhood. Some are drawing comparisons to past financial crises, adding a layer of caution to the enthusiasm.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is experiencing increased attention, with community members citing a potential breakout and government investment possibilities as catalysts. Discussions revolve around recent news, high call option activity, and the significance of rare earth elements for national security. The stock's breakout is leading to speculation about future price targets and institutional interest.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending as investors react to Berkshire Hathaway's acquisition of OXY's OxyChem unit, leading to discussions around debt reduction and potential share buybacks. Community perspectives are mixed, with some questioning the strategic rationale behind selling a profitable business unit while others see it as a necessary step to strengthen the balance sheet. The news has sparked debate about the company's future direction and exposure to oil price fluctuations.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses the implications of David Schwartz stepping down as CTO.  Bullish sentiment is fueled by discussions around institutional adoption, tokenization, and cross-border payment utility, with some speculating on significant price movement.  Despite positive news, XRP struggles to break the $3 mark, leading to frustration and debate about market manipulation and future potential.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors discuss its potential following Keybanc's Overweight rating and price target adjustment. Community members are focused on the company's key support level, potential for growth, and anticipation of a significant move upward. The stock's relationship to the broader building products sector and management's strategy are also being closely watched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?

Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Craig-Hallum initiated coverage of Immunome (IMNM) on Friday with a ‘Buy’ rating and a $26 price target, noting that the shares could trade up 45% or more in the firm's bull cases.The target implies an upside of about 165% from the stock’s closing price on Thursday. Shares of the company rose 7% at the time of writing.Heading into Varegacestat's late-stage topline data in desmoid tumors due in the second half and IM-1021's early-stage go/no-go proof of concept data in hematological and solid tumors late in the year or in early 2026, the firm believes these catalysts "skew risk/reward to the upside" and sees an attractive entry point, as per TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMNM">IMNM stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_9_42_56_AM_png_dda0252eb1.webp" alt="IMNM's Sentiment Meter and Message Volume as of 9:45 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="59"><figcaption>IMNM's Sentiment Meter and Message Volume as of 9:45 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> In August, Immunome said that it expects to report data from a late-stage study of Varegacestat “before the end of 2025” and that it is “well-positioned” to support a new drug application for it. &nbsp;The investigational drug received an Orphan Drug Designation from the U.S. Food and Drug Administration in November 2023. The designation is granted to a drug or biological product intended to prevent, diagnose, or treat a rare disease or condition, and Varegacestat aims to treat desmoid tumors, a rare, locally aggressive growth in the body's fibrous connective tissue.As for IM-1021, the company said last month that patients were recently dosed at the third dose level in an early-stage dose-escalation trial.According to data from Koyfin, all ten analysts covering IMNM rate it either ‘Buy’ or ‘Strong Buy’. The stock has an average price target of $23.56.IMNM stock is down 2% this year and approximately 26% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-biontech-rising-pre-market-today/chwIXnPRdqb">Why Did BioNTech Stock Surge 10% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’

Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.

Equity

Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.


Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?

ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

IMNM
Immunome Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMNM News

IMNM Immunome Inc